LSD1-IN-21

• UNSPSC Description:

  LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated LSD1 (Lysine specific demethylase-1) inhibitor, with an IC50 of 0.956 μM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity[1].

• Target Antigen:

  Histone Demethylase; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Epigenetics

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/lsd1-in-21.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC=C(C=C1)/C=N/NC2=C(C(C3=CC=C(C=C3)OC)=NC(SCC(C)C)=N2)C#N

• Molecular Weight:

  447.55

• References & Citations:

  [1]Tasneem S, et al. Synthesis, biological evaluation and docking studies of methylene bearing cyanopyrimidine derivatives possessing a hydrazone moiety as potent Lysine specific demethylase-1 (LSD1) inhibitors: A promising anticancer agents. Bioorg Chem. 2022 May 21;126:105885.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported